Brain Metastases: State of the Art and Innovative Targeted Therapies


  • Maria Caffo Neurosurgical Clinic, Department of Neuroscience, School of Medicine, University of Messina, Italy
  • Lucia Merlo Department of Neurosurgery, Trieste, Italy
  • Valeria Barresi Department of Human Pathology, School of Medicine, University of Messina, Italy
  • Ema Tot Neurosurgical Clinic, Department of Neuroscience, School of Medicine, University of Messina, Italy
  • Gerardo Caruso Neurosurgical Clinic, Department of Neuroscience, School of Medicine, University of Messina, Italy



Angiogenesis, brain metastases, graphene, microRNA, nanoparticles, targete therapy.


 Brain metastasis represents the most common intracranial tumor. The metastatic process involves the migration of a cancer cell from the bulk tumor into the surrounding tissue, extravasation from the blood vessels into the tissues, and formation of a secondary tumor. Patients affected by brain metastases are in need of a multidisciplinary approach that generally includes surgical treatment and radiation therapy. Conventional chemotherapies have generally produced disappointing results, possibly due to their limited ability to penetrate the blood-brain barrier. With new data regarding the biology of brain metastases, novel targeted therapies can be considered interesting and promising therapeutic options. Targeted therapies showed improved survival in patients with metastatic disease. The advent of new technologies such as graphene nanoparticles has led to the discovery of novel pathways that allow a better delivery of the therapeutic compounds to the brain.


Kyritsis AP, Markoula S, Levin VA. A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemother Pharmacol 2012; 69: 1-13.

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14: 48-54.

Svokos KA, Salhia B, Toms SA. Molecular biology of brain metastasis. Int J Mol Sci 2014; 15: 9519-30.

Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21: 107-12.

Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008; 88: 359-65.

Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21: 2529-36.

Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. Cancer 2008; 113: 2139-45.

Verger E, Gil M, Yaya R, Vinolas N, Villà S, Pujol T, Quintò L, Graus F. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61: 185-91.

Caruso G, Caffo M, Raudino G, Alafaci C, Salpietro FM, Tomasello F. Antisense oligonucleotides as an innovative therapeutic strategy in the treatment of high-grade gliomas. Rec Pat CNS Drug Discov 2010; 5: 53-69.

Caruso G, Caffo M, Pino MA, Raudino G. In: Atta-ur-Rahman, Ed. Frontiers in Clinical Drug Research - CNS and Neurological Disorders. Sharjah: Bentham Science, 69-115, 2013.

Caffo M, Barresi V, Caruso G, Cutugno M, La Fata G, Venza M, Alafaci C, Tomasello F. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci 2013; 14: 2135-74.

Steeg PS. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.

Beasley KD, Toms SA. The molecular pathobiology of metastasis to the brain: A review. Neurosurg Clin N Am 2011; 22: 7-14.

Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev 2008; 22: 559-74.

Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-23.

Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341-52.

Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002; 36: 115-24.

Lorger M, Krueger JS, O’Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin ανβ3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 2009; 106: 10666-71.

Ramakrishna R, Rostomily R. Seed, soil, and beyond: The basic biology of brain metastasis. Surg Neurol Int 2013; 4: S256-S64.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.

Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33-43.

Siomin VE, Vogelbaum MA, Kanner AA, Lee S, Suh JH, Barnett GH. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol 2004; 67: 115-21.

Walter J, Kuhn SA, Waschke A, Kalff R, Ewald C. Operative treatment of subcortical metastatic tumours in the central region. J Neurooncol 2011; 103: 567-73.

Iwadate Y, Namba H, Yamaura A. Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res 2000; 20: 573-7.

Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993; 79: 210-6.

Stark AM, Tscheslog H, Buhl R, Held-Feindt J, Medhorn HM. Surgical treatment for brain metastases: Prognostic factors and survival in 177 patients. Neurosurg Rev 2005; 28: 115-9.

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51.

Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008; 71: 64-70.

Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai SK, Wenz F. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008; 72: 1311-8.

Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, et al. The role of whole brain radiation therapy in the management of newly diagnosed bain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 17-32.

Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 1997; 21: 129-83.

Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 2011; 29: 279-86.

Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA. Black PM, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87: 34-40.

Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000; 47: 291-8.

Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998; 16: 3563-9.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-91.

Chang SD, Murphy M, Geis P, Martin DP, Hancock SL, Doty JR, Adler JR Jr. Clinical experience with image-guided robotic radiosurgery (the cyberknife) in the treatment of brain and spinal cord tumors. Neurol Med Chir (Tokyo) 1998; 38: 780-3.

Wang Z, Yuan Z, Zhang W, You J, Wang P. Brain metastasis treated with cyberknife. Chin Med J 2009; 122: 1847-50.

Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69: 972-80.<972::AID-CNCR2820690423>3.0.CO;2-P

Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-6.

Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004; 9: 68-79.

Paul MJ, Summers Y, Calvert H, Rustin G, Brampton MH, Thatcher N, Middleton MR. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12: 175-8.

Zhu W, Zhou L, Qian JQ, Qiu TZ, Shu YQ, Liu P. Temozolomide for treatment of brain metastases: A review of 21 clinical trials. World J Clin Oncol 2014; 5: 19-27.

Palmieri D, Bronder J, Herring J, Yoneda T, Weil RJ, Stark AM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190-8.

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10: R20.

Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007; 85: 311-7.

Braen AP, Perron J, Tellier P, Catala AR, Kolaitis G, Geng W. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol 2010; 3: 259-67.

Iwata H, Narabayashi M, Ito Y, Saji S, Fujiwara Y, Usami S, et al. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: Subset analysis of Japanese patients. Int J Clin Oncol 2013; 18: 621-8.

Yuan Y, Li XF, Chen JQ, Dong CX, Weng SS, Huang JJ. Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. OncoTargets Ther 2014; 7: 841-52.

Ishida A, Kanoh K, Nishisaka T, Miyazu Y, Iwamoto Y, Kohno N, Miyazawa T. Gefinitib as a first line of therapy in non-small cell lung cancer with brain metastases. Intern Med 2004; 43: 718-20.

Lai CS, Boshoff C, Falzon M, Lee SM. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 2006; 61: 91.

Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 2004; 15: 1042-7.

Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008; 53: 376-81.

Shen Y, Ruan M, Luo Q, Yu Y, Lu H, Zhu R, Chen L. Brain metastasis from follicular thyroid carcinoma: Treatment with sorafenib. Thyroid 2012; 22: 856-60.

Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117; 501-9.

Novello S, Camps C, Grossi F, Mazieres J, Abrey L, Vernejoux JM, et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011; 6: 1260-6.

Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012; 6: 391-405.

Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117: 1687-96.

Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: A new paradigm. Cancer J 2012; 18: 208-12.

Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-95.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107: 14903-8.

Dummer R, Rozati S, Eggmann N, Rinderknecht J, Goldinger SM. From chemotherapy to targeted treatment. Ann Oncol 2012; 23: 101-3.

Sandler A. Bevacizumab in non-small cell lung cancer. Clin Cancer Res 2007; 13: 4613-6.

Socinski MA, Langer CJ, Huang JE, Kolb MM, Wang L, Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-61.

De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010; 100: 443-7.

McDermott R, Gabikian P, Sarvaiya P, Ulasov I, Lesniak MS. Micrornas in brain metastases: Big things come in small packages. J Mol Med 2013; 91: 5-13.

Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 2011; 3: 716-29.

Mueller WC, Spector Y, Edmonston TB, Cyr BS, Jaeger D, Lass U, et al. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 2011; 16: 165-74.

Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011; 286: 1429-35.

Li L, Huang K, You Y, Fu X, Hu L, Song L, Meng Y. Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. Int J Oncol 2014; 44: 2111-20.

Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 2011; 71: 645-54.

Zhao C, Xu Y, Zhang Y, Tan W, Xue J, Yang Z, et al. Down-regulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep 2013; 30: 2027-34.

Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011; 129: 2621-31.

Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncol 2012; 14: 689-700.

Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-9.

Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17: 7654-63.

Caruso G, Caffo M, Alafaci C, Raudino G, Cafarella D, Lucerna S, Salpietro FM, Tomasello F. Could nanoparticles systems have a role in the treatment of cerebral gliomas? Nanomedicine 2011; 7: 744-52.

Caruso G, Marino D, Caffo M. Nanoparticles and CNS delivery of therapeutic agents in the treatment of primary brain tumors. J Analyt Oncol 2014; 3: 105-12.

Caffo M, Merlo L, Marino D, Caruso G. Graphene in neurosurgery: The beginning of a new era. Nanomedicine 2015; 10: 615-625.

Shen H, Zhang L, Liu M, Zhang Z. Biomedical applications of graphene. Theranostics 2012; 2: 283-94.

Liu G, Shen H, Mao J, Zhang L, Jiang Z, Sun T, et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. ACS Appl Mater Interfaces 2013; 5: 6909-14.

Yang HW, Hua MY, Hwang TL, Lin KJ, Huang CY, Tsai RY, et al. Non-invasive synergistic treatment of brain tumors by targeted chemotherapeutic delivery and amplified focused ultrasound-hyperthermia using magnetic nanographene oxide. Adv Mater 2013; 25: 3605-11.

Wang H, Gu W, Xiao N, Ye L, Xu Q. Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug. Int J Nanomedicine 2014; 9: 1433-42.

Yang K, Wan J, Zhang S, Tian B, Zhang Y, Liu Z. The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. Biomaterials 2012; 33: 2206-14.




How to Cite

Maria Caffo, Lucia Merlo, Valeria Barresi, Ema Tot, & Gerardo Caruso. (2015). Brain Metastases: State of the Art and Innovative Targeted Therapies. Journal of Analytical Oncology, 4(3),  113–121.




Most read articles by the same author(s)